Melanoma treatment included surgery (90.9%, n = 10), radiation (9.1%, n = 1), and systemic therapy (e.g., cytotoxic chemotherapy, cytokine-based immunotherapy, or targeted) (81.8%, n = 9), with 54.5% (n = 6) receiving immune checkpoint inhibitors (ICI) (e.g., PD-1 and/or CTLA-4 inhibitor). This evidence concerns the gene CTLA4 and melanoma.